This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

4 Biotech Stocks Under $10 With Relative Strength


Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Immunomedics (IMMU - Get Report) is a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. This stock is trading up 4.4% at $3.51 in recent trading.

Today's Range: $3.42-$3.65

52-Week Range: $2.85-$4.27

Volume: 403,000

Three-Month Average Volume: 278,730

Shares of IMMU are soaring today after the company said that their scientists have published an article in the current issue of the journal, PLoS One, describing their collaboration in the design and testing of a new class of drugs that significantly destroyed the AIDS virus, HIV, and may potentially eradicate the virus completely.

>>Hot Biotech Stocks Traded by Hedge Funds

From a technical perspective, IMMU is soaring here back above its 200-day at $3.45 and its 50-day moving averageat $3.47 with heavy volume. This stock has also briefly flirted with a near-term breakout today, since shares have challenged some overhead resistance at $3.60. At last check, IMMU has hit an intraday high of $3.65 and volume is well above its three-month average action of 278,730 shares.

Traders should now look for long-biased trades as long as IMMU is trending above $3.60 to $3.76 with strong upside volume flows. I would consider any upside volume day that registers near or above 278,730 shares as bullish. If we get that action for IMMU, then I expect this stock to re-test and possibly take out $4 to $4.45 in the near future.
3 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CRTX $0.00 0.00%
DNDN $0.06 -6.02%
IMMU $3.20 0.00%
PLX $1.09 0.00%
AAPL $118.03 0.00%


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs